What is Enliven Therapeutics's operating lease liabilities?

Enliven Therapeutics (ELVN) reported operating lease liabilities of -$97K in Q1 2026.

How has Enliven Therapeutics's operating lease liabilities changed year-over-year?

Enliven Therapeutics's operating lease liabilities decreased by 40.6% year-over-year, from -$69K to -$97K.

What is the long-term trend for Enliven Therapeutics's operating lease liabilities?

Over 2 years (2023 to 2025), Enliven Therapeutics's operating lease liabilities has grown at a 4.3% compound annual growth rate (CAGR), from -$310K to -$337K.

Enliven Therapeutics ELVN Operating lease liabilities

Operating lease liabilities at other companies

Iovance Biotherapeutics, Inc.IOVA

——

ImmunomeIMNM

——

ArriVent BioPharma, Inc.AVBP

——

BillionToOne, Inc. BLLN

——

Vir Biotechnology, Inc.VIR

——

Crinetics PharmaceuticalsCRNX

——

Other financials

Income statement

See full

Operating income-$27.8M+12.2%

Net income-$23.6M+17.2%

EPS (diluted)-$0.38+33.3%

Balance sheet

See full

Cash & equivalents$132.2M+30.0%

Total debt$302.0K-56.9%

Total equity$453.4M+57.3%

Total assets$464.9M+53.6%

Cash flow

See full

Operating cash flow-$19.3M+20.0%

CapEx--100%

Free cash flow-$19.3M+20.1%

Valuation

See full

Market cap$3.47B+143%

Enterprise value$3.34B+156%

Returns & leverage

See full

Return on equity-26.6%-3.5pp

Debt / equity0×0.0×

Current ratio40.3×+19.3×

Where this comes from

Reported directly by Enliven Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enliven Therapeutics's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Enliven Therapeutics's operating lease liabilities?: Enliven Therapeutics (ELVN) reported operating lease liabilities of -$97K in Q1 2026.
How has Enliven Therapeutics's operating lease liabilities changed year-over-year?: Enliven Therapeutics's operating lease liabilities decreased by 40.6% year-over-year, from -$69K to -$97K.
What is the long-term trend for Enliven Therapeutics's operating lease liabilities?: Over 2 years (2023 to 2025), Enliven Therapeutics's operating lease liabilities has grown at a 4.3% compound annual growth rate (CAGR), from -$310K to -$337K.